Alcohol Addiction - Pipeline Review, H1 2020

January 2020 | 183 pages | ID: A353C411E98EN
Global Markets Direct

Abstracts

Alcohol Addiction - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alcohol Addiction - Pipeline Review, H1 2020, provides an overview of the Alcohol Addiction (Central Nervous System) pipeline landscape.

Alcohol addiction refers to a psychological and physical dependency on alcohol. Symptoms include decreased involvement in extracurricular activities, depression, restlessness, inability to control drinking and violent behavior. Risk factors include age, family history and depression and other mental health problems.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alcohol Addiction - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Alcohol Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alcohol Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Alcohol Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 9, 5, 21, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Alcohol Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Alcohol Addiction (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Alcohol Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Alcohol Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Alcohol Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Alcohol Addiction (Central Nervous System)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Alcohol Addiction (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Alcohol Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Alcohol Addiction - Overview
Alcohol Addiction - Therapeutics Development
Alcohol Addiction - Therapeutics Assessment
Alcohol Addiction - Companies Involved in Therapeutics Development
Alcohol Addiction - Drug Profiles
Alcohol Addiction - Dormant Projects
Alcohol Addiction - Discontinued Products
Alcohol Addiction - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Alcohol Addiction, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Alcohol Addiction - Pipeline by Adial Pharmaceuticals Inc, H1 2020
Alcohol Addiction - Pipeline by Amygdala Neurosciences Inc, H1 2020
Alcohol Addiction - Dormant Projects, H1 2020
Alcohol Addiction - Dormant Projects, H1 2020 (Contd..1), H1 2020
Alcohol Addiction - Dormant Projects, H1 2020 (Contd..2), H1 2020
Alcohol Addiction - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Alcohol Addiction, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

Adial Pharmaceuticals Inc
Amygdala Neurosciences Inc
Aptinyx Inc
Arbor Pharmaceuticals LLC
Assuage Pharmaceuticals Inc
Astraea Therapeutics LLC
AstraZeneca Plc
Avicanna Inc
BioCorRx Inc
Bioprojet SCR
Chronos Therapeutics Ltd
Colorado Research Partners LLC
Confluence Pharmaceuticals LLC
Corcept Therapeutics Inc
Curemark LLC
Dicerna Pharmaceuticals Inc
Eli Lilly and Co
Kinnov Therapeutics SAS
Kinoxis Therapeutics Pty Ltd
Kyorin Pharmaceutical Co Ltd
Laboratorio Farmaceutico CT Srl
Lohocla Research Corp
Mapreg SAS
Mind Medicine Inc
Montisera Ltd
Omeros Corp
Opiant Pharmaceuticals Inc
Osmotica Pharmaceutical Corp
Pfizer Inc
SK Biopharmaceuticals Co Ltd
Sosei Heptares
South Plains Biotechnology Inc
Syntropharma Ltd
Tonix Pharmaceuticals Holding Corp
VM Discovery Inc
Zynerba Pharmaceuticals Inc